Spruce Biosciences, Inc.

Spruce Biosciences, Inc.

Spruce Biosciences, Inc.

Overview
Headquarters

2001 Junipero Serra Boulevard, Suite 640, Daly City, CA, 94014, USA

Type of Company

Public

Employees (Worldwide)

1 - 10

Industries

Biotechnology
Hospitals & Patient Services

Company Description

Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The firm is initially developing its wholly-owned product candidate, tildacerfont, as the non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).The company was founded on November 13, 2014 and is headquartered in Daly City, CA.

Executives & Employees

Executive Chairman & Chief Executive Officer

Chief Financial Officer

Chief Medical Officer

Executive Medical Director

Vice President, Development Operations

Board of Directors

Co-Founder at Mirum Pharmaceuticals, Inc.

Paths to Spruce Biosciences, Inc.
Potential Connections via
Relationship Science
You
Spruce Biosciences, Inc.
Owners & Shareholders
Details Hidden

Novo Holdings-IC to seeks to grow the assets of the Foundation and creates positive impact on health, science and society by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Details Hidden

RiverVest Venture partners focuses on investments in early-stage life sciences companies with emphasis on the medical device and biopharmaceutical industries. The firm provides financing for early and later stage capital requirements.

Details Hidden

Omega Fund Management invests in private and public companies located in the US and Europe. The firm targets companies operating in the fields of biotechnology, life sciences, healthcare and medical devices. They provides financing for seed, early, mid and later stage capital requirements. The firm considers direct secondary investments and also makes follow-on investments.

Recent Transactions
Details Hidden

Spruce Biosciences, Inc. issued USD Common Stock

Details Hidden

Spruce Biosciences, Inc. raised money in a private placement transaction

Transaction Advisors
Auditor

Advised onSpruce Biosciences, Inc. issued USD Common Stock

Escrow Agent

Advised onSpruce Biosciences, Inc. issued USD Common Stock

Legal Advisor

Advised onSpruce Biosciences, Inc. issued USD Common Stock

Key Stats and Financials As of 2020
Market Capitalization
$63.1M
Total Enterprise Value
$415M
Earnings Per Share
$-1.27
Total Equity
$149M
Net Profit
$-29.5M
Revenue
$0
Debt TEV
0.02x
TEVNet Income
-14.04x
Total Debt
$6.38M
EBITDA
$-29.3M
Investors
Details Hidden

RiverVest Venture partners focuses on investments in early-stage life sciences companies with emphasis on the medical device and biopharmaceutical industries. The firm provides financing for early and later stage capital requirements.

Details Hidden

Omega Fund Management invests in private and public companies located in the US and Europe. The firm targets companies operating in the fields of biotechnology, life sciences, healthcare and medical devices. They provides financing for seed, early, mid and later stage capital requirements. The firm considers direct secondary investments and also makes follow-on investments.

Details Hidden

Abingworth Bioventures invests in private and public companies located across the UK, Europe and the US. The firm targets companies operating in the fields of medical devices, instrumentation, bio therapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics and instrumentation. They provide financing for seed, early and later-stage capital requirements with an investment size ranging from $15 million to $30 million. It also makes majority or minority investments.

Suppliers
Eli Lilly & Company Hospitals & Patient Services

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo.The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Competitors
Neurocrine Biosciences Inc. Biotechnology - San Diego, CA

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

BridgeBio Pharma, Inc. Biotechnology - Palo Alto, CA

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Crinetics Pharmaceuticals, Inc. Pharmaceuticals - San Diego, California

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Spruce Biosciences, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Spruce Biosciences, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Spruce Biosciences, Inc..